CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...
Cargo Therapeutics stock rating cut by Jefferies to Hold
Jefferies analysts downgraded Cargo Therapeutics (NASDAQ:CRGX) shares from Buy to Hold, significantly reducing the price target to $3.00 from the previous $32.00. The stock, currently trading at ...
CARGO halts Phase 2 study of cancer treatment
SAN CARLOS, Calif. - CARGO Therapeutics , Inc. (NASDAQ:CRGX), a clinical-stage biotech company currently valued at $628 ...
Cargo Therapeutics to discontinue FIRCE-1 Phase 2 study of Firi-cel
CARGO Therapeutic announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 ...
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
Detailed price information for Cargo Therapeutics Inc (CRGX-Q) from The Globe and Mail including charting and trades.